The acquisition of lead compounds and the production of drugs are important links in the process of drug screening. Drug screening involves a series of steps to select the most suitable chemical entity for drug development to clinical application, including pharmacological research and toxicological research. Research to determine the safety and effectiveness of the drug. Receptor-ligand binding analysis is an important drug screening method. It uses in vitro experiments to investigate the binding ability of ligands (drugs) and receptors, and plays an important role in drug structure design and new drug screening.
Quantitative analysis of drugs, metabolites, proteins and peptides in biological matrices using biological analysis techniques such as chromatography, chromatography-mass spectrometry, and ligand binding has been widely used in the process of drug discovery and drug research. Ligand Binding Assay (Ligand Binding Assay, LBA) is one of the common analysis methods. LBA is a common biological analysis tool that can quantitatively determine the concentration of biological molecules such as target analytes and Analyte in biological fluids based on the binding and interaction with other biological molecules.
Ligand Binding Assay is often used as a kind of immunoassay to find a specific ligand based on a target protein. Such a target is a receptor in many cases. At present, it has been found that in addition to some small molecules of hormones, some peptides, DNA and even RNA can also interact with the target protein.
In order to accurately detect the bound ligand, we usually need a label, and the bound ration can be directly detected by this label, or combined with other detectable substances to determine. Another advantage of choosing a highly specific marker is that it can avoid tedious separation and purification processes during screening. Crude cell extracts or samples that have undergone simple membrane separation can be used for screening.
For the research and development of peptide drugs, LBA is also a common method for analyzing peptide drugs. It is based on the specific recognition of analytes/antigens by antibodies to quantitatively analyze target peptides, mainly including enzyme-linked immunoassay (ELISA) and radioimmunoassay. Method (RIA), electrochemiluminescence (MSD), etc. Compared with other detection methods, ELISA has the advantages of low cost, simple operation, fast speed, high sensitivity, high throughput, and no radioactive hazards. In the analysis of peptide biotechnology drugs, Medicilon Biotechnology Drug Analysis Department flexibly uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biology Drugs such as proteins, antibodies (monoclonal antibodies, bi- or multispecific antibodies, antibody fragments), ADCs, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity (Total ADA& Nab)/Biomarker&Cytokine and other research evaluations.
Bioanalysis is an important part of the drug development process, which runs through the entire process of drug development from early screening to clinical research to post-marketing monitoring. The use of high-quality, high-sensitivity bioanalysis techniques to obtain reliable data can promote the development of drugs. As a commonly used method in biological analysis, the LBA method has a lower detection limit and is the preferred method for analyzing biological samples. It is the main quantitative analysis method for evaluating the PK/TK of biological drugs. With the advancement of science and technology, there will also be more sensitive, less sample volume requirements, shorter analysis cycle, higher repeatability, full automation and other advantages of bioanalysis technology will be developed to provide more reliable analysis of biotechnology drugs.
Relevant
news
marketing@medicilon.com
